News
New programme celebrates ChargePoint Technology’s role in COVID-19 vaccine rollout
Specialist Merseyside manufacturing business ChargePoint Technology is set to appear in an ITN production exploring its role in helping to bring the first COVID-19 vaccine to market.
The company will feature in the upcoming programme “How Vaccines Are Changing The...
News
Rinvoq, Blockbuster Drug From Abbvie Gets Fourth FDA Nod
The pharma version of Fast and Furious has a new superhero. How else to characterise AbbVie's Rinvoq's breakthrough effectiveness? The immunology medicine received its fourth FDA approval in five months on April 29th for ankylosing spondylitis. The blessing, however, came...
News
Starting The Journey Dupixent From Sanofi Puts A Good Show
Sanofi's Dupixent is still breaking new ground in inflammatory illnesses five years after receiving FDA approval for the first time in eczema. Bill Sibold, Sanofi's global head of speciality care, believes this since the Regeneron-partnered drug's first-quarter sales increased...
News
Carcinogen Concern Leads To Pfizer Drug Recall From The US
Pfizer's recall saga has now reached the United States, after elevated concentrations of potential carcinogens forced the company to pull multiple products in Canada. After testing revealed quantities of a nitrosamine—Nnitroso-quinapril—above daily recommended limits, Pfizer is recalling five lots...
News
Catalent Buys A NJ Cell Therapy Facility For $44.5 Million
Catalent, the high-flying CDMO, is buying a cell therapy unit on the East Coast, only days after spending $350 million to strengthen up biologics production in Indiana.
Catalent announced on April 25th that it had paid $44.5 million for Erytech...
News
First Malaria Vaccine Protects Around A Million African Kids
More than a million children in Ghana, Kenya, and Malawi have been given one or more doses of the world’s first malaria vaccine, owing to a pilot programme supervised by WHO, as World Malaria Day approaches this year. The...
News
NorthX Biologics signs GMP manufacturing collaboration agreement with Abera Bioscience
Sweden-based NorthX Biologics, which focuses on process development and large-scale production of advanced biological drugs, has signed a collaboration agreement with Abera Bioscience for upscaling and GMP manufacturing of its vaccine candidate against pneumococcus, Ab-01.12.
NorthX has recently established an...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read